Cowen Downgrades Celldex Therapeutics (CLDX) to Market Perform

UPDATE: Cantor Fitzgerald Downgrades Celldex Therapeutics (CLDX) to Neutral, 'Glemba in Rear View Mirror'

(Updated - April 17, 2018 6:45 AM EDT)

(updated to add analyst comment)

Cantor Fitzgerald downgraded Celldex Therapeutics (NASDAQ: CLDX) from Overweight to Neutral with a price target of $3.00 (from $9.00).

Analyst Mara Goldstein comments "We had ascribed $6/share in value to... More

Celldex Therapeutics (CLDX) PT Lowered to $1 at Jefferies; 'METRIC PIII Trial Fails'

Jefferies lowered its price target on Celldex Therapeutics (NASDAQ: CLDX) to $1.00 (from $3.00) while maintaining a Hold rating.

Celldex Therapeutics (CLDX) PT Lowered to $2.50 at H.C. Wainwright

H.C. Wainwright lowered its price target on Celldex Therapeutics (NASDAQ: CLDX) to $2.50 (from $10.00) while maintaining a Buy rating.

Analyst Joseph Pantginis commented, "This morning, Celldex announced that the Phase 2b METRIC Study of glembatumumab vedotin compared to Xeloda in patients with metastatic... More

Pre-Open Stock Movers 04/16: (ERI) (ALKS) (DVAX) Higher; (CLDX) (ALGT) (NLNK) Lower (more...)

Celldex (NASDAQ: CLDX) 49% LOWER; announcing its Phase 2b METRIC Study of glembatumumab vedotin compared to Xeloda in patients with metastatic triple-negative breast cancers that overexpress gpNMB failed to meet its primary endpoint.

Eldorado Resorts, Inc. (NASDAQ: ERI) 14.8% HIGHER; entered into a definitive agreement to acquire Tropicana Entertainment Inc. (OTCQB: TPCA) in a cash transaction that is valued at $1.85 billion. The definitive agreement provides that Gaming and Leisure Properties (NASDAQ:... More

Celldex (CLDX) Set to Open Lower By 49% After METRIC Study Fails

Celldex (NASDAQ: CLDX) was set to open lower by 49% Monday morning after announcing its Phase 2b METRIC Study of glembatumumab vedotin compared to Xeloda in patients with metastatic triple-negative breast cancers that overexpress gpNMB failed to meet its primary endpoint.

Celldex (CLDX) Announces Phase 2B METRIC Study in Metastatic Triple-negative Breast Cancer Does Not Meet Primary Endpoint

Celldex Therapeutics, Inc. (NASDAQ: CLDX) today reported that the Companys randomized, Phase 2b METRIC Study of glembatumumab vedotin compared to Xeloda® (capecitabine) in patients with metastatic triple-negative breast cancers that overexpress gpNMB failed to meet its primary endpoint, progression-free survival (PFS) as assessed by an independent, central reading of patient scans (Hazard ratio = 0.95; median PFS: glembatumumab vedotin 2.9 months vs. Xeloda 2.8 months; p=0.76). There was no significant advantage for glembatumumab vedotin in key secondary endpoints, including overall response rate, duration of response and overall survival. The glembatumumab vedotin safety profile was consistent with prior... More